Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2019.07.001
Abstract: INTRODUCTION Patients with residual disease usually have a poor prognosis after neoadjuvant chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential additional adjuvant treatments for patients with residual… read more here.
Keywords: rcb iii; breast cancer; neoadjuvant chemotherapy; cancer ... See more keywords
Abstract P2-04-07: Immune profiling of post neoadjuvant high metastatic risk (RCB-II/III) residual disease in patients with early triple negative breast cancers
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs16-p2-04-07
Abstract: Background: Poor prognosis in TNBC can be predicted in the significant fraction of patients with large volume residual cancer burden (RCB-II/III) after neoadjuvant chemotherapy (NACT). Whilst residual disease has been characterised to identify “driver” mutations… read more here.
Keywords: high metastatic; rcb iii; metastatic risk; disease ... See more keywords